Literature DB >> 21316780

Computational design of peptide ligands.

Peter Vanhee1, Almer M van der Sloot, Erik Verschueren, Luis Serrano, Frederic Rousseau, Joost Schymkowitz.   

Abstract

Peptides possess several attractive features when compared to small molecule and protein therapeutics, such as high structural compatibility with target proteins, the ability to disrupt protein-protein interfaces, and small size. Efficient design of high-affinity peptide ligands via rational methods has been a major obstacle to the development of this potential drug class. However, structural insights into the architecture of protein-peptide interfaces have recently culminated in several computational approaches for the rational design of peptides that target proteins. These methods provide a valuable alternative to experimental high-resolution structures of target protein-peptide complexes, bringing closer the dream of in silico designed peptides for therapeutic applications.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 21316780     DOI: 10.1016/j.tibtech.2011.01.004

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  35 in total

Review 1.  Natural products as sources of new drugs over the 30 years from 1981 to 2010.

Authors:  David J Newman; Gordon M Cragg
Journal:  J Nat Prod       Date:  2012-02-08       Impact factor: 4.050

2.  A lanthanide-peptide-derived bacterium-like nanotheranostic with high tumor-targeting, -imaging and -killing properties.

Authors:  Wangxiao He; Jin Yan; Lijuan Wang; Bo Lei; Peng Hou; Wuyuan Lu; Peter X Ma
Journal:  Biomaterials       Date:  2019-03-21       Impact factor: 12.479

3.  Design of peptide affinity ligands for S-protein: a comparison of combinatorial and de novo design strategies.

Authors:  Divya Chandra; Christopher J Morrison; James Woo; Steven Cramer; Pankaj Karande
Journal:  Mol Divers       Date:  2013-03-27       Impact factor: 2.943

Review 4.  Peptide aptamers: development and applications.

Authors:  Sergey Reverdatto; David S Burz; Alexander Shekhtman
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

5.  HSymM-guided engineering of the immunodominant p53 transactivation domain putative peptide antigen for improved binding to its anti-p53 monoclonal antibody.

Authors:  Zachary R Fritz; Rene S Schloss; Martin L Yarmush; Lawrence J Williams
Journal:  Bioorg Med Chem Lett       Date:  2021-08-26       Impact factor: 2.823

6.  PEP-SiteFinder: a tool for the blind identification of peptide binding sites on protein surfaces.

Authors:  Adrien Saladin; Julien Rey; Pierre Thévenet; Martin Zacharias; Gautier Moroy; Pierre Tufféry
Journal:  Nucleic Acids Res       Date:  2014-05-06       Impact factor: 16.971

7.  Avidity-controlled delivery of angiogenic peptides from injectable molecular-recognition hydrogels.

Authors:  Widya Mulyasasmita; Lei Cai; Yuki Hori; Sarah C Heilshorn
Journal:  Tissue Eng Part A       Date:  2014-02-03       Impact factor: 3.845

Review 8.  Targeting protein-protein interactions as an anticancer strategy.

Authors:  Andrei A Ivanov; Fadlo R Khuri; Haian Fu
Journal:  Trends Pharmacol Sci       Date:  2013-05-29       Impact factor: 14.819

9.  Rational design of type-IA receptor-derived cyclic peptides to target human bone morphogenic protein 2.

Authors:  Xiaohua Fan; Hai Xia; Xiaoyun Liu; Benying Li; Jun Fang
Journal:  J Biosci       Date:  2019-12       Impact factor: 1.826

10.  Bioportide: an emergent concept of bioactive cell-penetrating peptides.

Authors:  John Howl; Sabine Matou-Nasri; David C West; Michelle Farquhar; Jiřina Slaninová; Claes-Göran Ostenson; Matjaz Zorko; Pernilla Ostlund; Shant Kumar; Ulo Langel; Jane McKeating; Sarah Jones
Journal:  Cell Mol Life Sci       Date:  2012-04-20       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.